Lisata Therapeutics (LSTA)

Lisata Therapeutics (LSTA) Stock Price & Analysis


LSTA Stock Chart & Stats

Day’s Range$0 - $0
52-Week Range$1.95 - $4.53
Previous Close$2.58
Average Volume (3M)20.37K
Market Cap
Enterprise Value-$34.64M
Total Cash (Recent Filing)$54.39M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)-1.0
Mar 28, 2024
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.68
Shares Outstanding8,139,449
10 Day Avg. Volume26,704
30 Day Avg. Volume20,374
Standard Deviation0.18
Financial Highlights & Ratios
Price to Book (P/B)0.38
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-1.40
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-10.00T>
Enterprise Value/Ebitda1.39
Price Target Upside474.71% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1




What was Lisata Therapeutics’s price range in the past 12 months?
Lisata Therapeutics lowest stock price was $1.95 and its highest was $4.53 in the past 12 months.
    What is Lisata Therapeutics’s market cap?
    Currently, no data Available
    When is Lisata Therapeutics’s upcoming earnings report date?
    Lisata Therapeutics’s upcoming earnings report date is Mar 28, 2024 which is in 110 days.
      How were Lisata Therapeutics’s earnings last quarter?
      Lisata Therapeutics released its earnings results on Nov 02, 2023. The company reported -$0.65 earnings per share for the quarter, beating the consensus estimate of -$0.93 by $0.28.
        Is Lisata Therapeutics overvalued?
        According to Wall Street analysts Lisata Therapeutics’s price is currently Undervalued. Get more investment ideas with TipRanks Premium
          Does Lisata Therapeutics pay dividends?
          Lisata Therapeutics does not currently pay dividends.
          What is Lisata Therapeutics’s EPS estimate?
          Lisata Therapeutics’s EPS estimate is -$0.86.
            How many shares outstanding does Lisata Therapeutics have?
            Lisata Therapeutics has 8,139,449 shares outstanding.
              What happened to Lisata Therapeutics’s price movement after its last earnings report?
              Lisata Therapeutics reported an EPS of -$0.65 in its last earnings report, beating expectations of -$0.93. Following the earnings report the stock price went up 8.257%.
                Which hedge fund is a major shareholder of Lisata Therapeutics?
                Among the largest hedge funds holding Lisata Therapeutics’s share is RA Capital Management. It holds Lisata Therapeutics’s shares valued at N/A.


                  Lisata Therapeutics Stock Smart Score

                  Company Description

                  Lisata Therapeutics

                  Caladrius Biosciences, Inc. is a biopharmaceutical company, which engages in developing products in cardiovascular and autoimmune disease that have the potential to restore the health of people with chronic illnesses. Its product pipeline includes CLBS12, CLBS14, and CLBS03. The company was founded on September 18, 1980 and is headquartered in Basking Ridge, NJ.


                  Top 5 ETFs holding LSTA

                  Market Value
                  Smart Score
                  Vanguard Total Stock Market ETF
                  iShares Core S&P Total U.S. Stock Market ETF
                  Up to five ETFs with an Outperform Smart Score that hold LSTA. The ETFs are listed according to market value of LSTA within the ETF

                  Forecast EPS vs Actual EPS

                  Similar Stocks
                  Price & Change
                  Adverum Biotechnologies
                  Biohaven Ltd.
                  Arvinas Holding Company

                  Popular Stocks

                  What's Included in PREMIUM?
                  Make informed decisions based on Top Analysts' activity
                  Know what industry insiders are buying
                  Get actionable alerts from top Wall Street Analysts
                  Find out before anyone else which stock is going to shoot up
                  Get powerful stock screeners & detailed portfolio analysis